secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K/A
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001178913-22-004189
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab appoints Matthew Frankel as Chief Medical Officer & VP Drug Development
--------------------------------------------------------------------------------

- Start Date November 14, 2022; report to Chairman & CEO Dale Pfost.
- Annual base salary of $450,000; target performance bonus of 45% of base salary.
- Special milestone bonuses: $100,000 after 60 days, $100,000 after 120 days.
- Granted option to purchase 125,000 ADSs vesting over 4 years (25% annual, rest monthly).
- Employment is at-will; governed by New York law with mandatory arbitration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/0001178913-22-004189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/zk2228824.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-004189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer